Skip to main content
To the Editor: The correlational relationship between psychotic symptoms and functional outcome is weak, as Gordon and Green note. However, it is another matter to conclude that antipsychotic medication is not relevant to community functioning, quality of life, and well-being. A minority of studies hint at an advantage for work functioning for unmedicated patients (1). In contrast, we and others have found a number of advantages of consistent use of antipsychotic medication that extend beyond symptom control, notably improvement in cognition (2), brain myelination (3), and work productivity (25).
The Subotnik et al. (4) study of medication nonadherence and return of psychosis was conducted in the context of a project that aimed to help people with recent onset of schizophrenia pick up where they left off at work or school, as quickly as possible, to avoid the demoralization that accompanies chronic disability. We used individual placement and support (IPS) integrated into the treatment team at the UCLA Aftercare Research Program to accomplish this (6), and we were quite successful at getting patients back to work or school (7). We believe that there is a synergistic effect of medication and IPS, as medication improves a patient's potential for work recovery and IPS helps to actualize that potential.
We also agree that individuals with schizophrenia appear to learn about their illness over time, and their awareness of having a mental disorder generally improves over the initial phase of illness (8). However, we think that the learning is optimized when a review of past symptoms occurs after the psychotic symptoms have eased, and this is most likely to happen after consistent use of antipsychotic medication.
Our findings about nonadherence to risperidone are in the context of a protocol that strongly encouraged adherence to the dosage that was tailored to each individual's needs. Nonadherence was often accompanied by poor insight regarding the benefits of medication. It is possible that nonadherence was in some instances triggered by an undetected brewing storm of subclinical symptomatic and psychophysiological changes that also made the effects of brief periods of partial nonadherence even more hazardous. This situation is quite different from that of a shared decision to start an off-medication trial for a person who has been doing very well over an extended period. In that context, the return of psychosis is not as swift (approximately 8 months [9]) as it is in the case of nonadherence to medication as prescribed (approximately 2.5 months [10]). If an off-medication trial is pursued collaboratively, we recommend careful and perhaps more frequent clinical monitoring, with family involvement to alert the treatment team to any early warning signs of relapse. Physicians should not abandon their patients during an off-medication trial that reflects shared decision making, and there is no reason for patients to similarly abandon their physicians. Both need to recognize the high likelihood that psychotic symptoms will return, as well as the emerging evidence that consistent antipsychotic treatment has a neuroprotective effect (3, 11). Small increases in positive symptoms can sometimes be handled with a psychosocial intervention without a resumption of medication. However, a significant exacerbation or relapse following a period of medication nonadherence or an off-medication trial is a clear signal that medication needs to be resumed.

Footnote

Accepted for publication in June 2011.

References

1.
Johnstone EC, Macmillan JF, Frith CD, Benn DK, Crow TJ: Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry 1990; 157:182–189
2.
Nuechterlein K, Subotnik K, Ventura J, Gretchen-Doorly D, Casaus L, Luo J, Detore NR, Victoria A, Kurtz AS: The cognitive effects of long-acting injectable vs oral second-generation antipsychotic medication after an initial psychotic episode. International Society for CNS Clinical Trials and Methodology 2010 Autumn Conference, Baltimore, 2010. http://isctm.org/public_access/2010_13Oct_Posters_Abstracts.pdf
3.
Bartzokis G, Lu PH, Raven EP, Amar CP, DeTore NR, Altshuler LL, Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH: Abnormal trajectory of intracortical myelination in schizophrenia implicates white matter in treatment response and outcomes. Biol Psychiatry 2011; 69(suppl 1):185S
4.
Subotnik KL, Ventura J, Gretchen-Doorly D, Luo JS, Casaus LR, Hellemann GS, Victoria A, Nuechterlein KH: Effectiveness of risperidone long-acting injection in the early phase of schizophrenia: relapse prevention and symptom reduction. Abstracts of the 13th International Congress on Schizophrenia Research (ICOSR), April 2–6, 2011, Colorado Springs, Colo. Schizophr Bull 2011; 37(suppl 1):1–342
5.
Keith S: Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety, and cost-effectiveness. Expert Rev Neurother 2009; 9:9–31
6.
Nuechterlein KH, Subotnik KL, Turner LR, Ventura J, Becker DR, Drake RE: Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment. Psychiatr Rehabil J 2008; 31:340–349
7.
Nuechterlein KH, Subotnik KL, Turner L, Ventura J, Gitlin MJ, Gretchen-Doorly D, Becker DR, Drake RE, Wallace CJ, Liberman RP: Successful Return to Work or School in Recent-Onset Schizophrenia: The UCLA Randomized Controlled Trial of Individual Placement and Support. 2nd Biennial Schizophrenia International Research Society Conference, April 10–14, 2010, Florence, Italy
8.
Subotnik KL, Nuechterlein KH, Green MF, Horan WP, Ventura J, Luo JS (eds): Insight Into Illness in the Early and Chronic Phases of Schizophrenia. Presented at the Society for Research in Psychopathology, 2006, San Diego, Calif
9.
Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158:1835–1842
10.
Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168:286–292
11.
Bartzokis G, Lu PH, Amar CP, Raven EP, Detore NR, Altshuler LL, Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH: Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res (Epub ahead of print, Jul 16, 2011)

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 987 - 988
PubMed: 21890806

History

Accepted: June 2011
Published online: 1 September 2011
Published in print: September 2011

Authors

Details

Kenneth L. Subotnik, Ph.D.
Keith H. Nuechterlein, Ph.D.
Joseph Ventura, Ph.D.
Stephen Marder, M.D.

Funding Information

The authors' disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share